Advertisement

Topics

Exon-Intron, Inc. Company Profile

05:26 EDT 24th September 2018 | BioPortfolio

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of virtually every level of sophistication. By placing great emphasis on hands-on, laboratory-intensive training, our workshops provide the researcher with the necessary skills and insight to plan and perform cutting-edge research, and to interpret the resulting data. These programs are comprehensive and provide the participant with enough knowledge to be conversant in the language of biotechnology and to teach these methods to students in all areas of science.

Location

P.O. Box 395
Loganville
Pennsylvania
17342
United States of America

Contact

Phone: 717-428-3780
Fax: 717-771-4062
Email: workshop@DNAtech.com


News Articles [34 Associated News Articles listed on BioPortfolio]

FDA Approves Frontline Osimertinib for NSCLC

The FDA has approved osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitut...

Intron retention is a source of neoepitopes in cancer

FDA approves osimertinib as first line treatment for EGFRm NSCLC

The US Food and Drug Administration (FDA) has approved osimertinib for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth facto...

Instantaneous Single-Cell Transcriptome Visualization

Being able to see precisely when various genes are turned on and off, as well as spatially visualizing the whole transcriptome at once has been challenging for single-cell analysis. However now, Calte...

AZ's Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from the FDA for the first-line treatment of met...

FDA Approves AstraZeneca’s Tagrisso as First-Line Therapy for EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCL...

Clinical and molecular consequences of exon 78 deletion in DMD gene

Terminal exon characterization with TECtool reveals an abundance of cell-specific isoforms

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin capsules. Ribavirin Capsules Initial U.S. Approval: ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

Ribavirin [American Health Packaging]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

PubMed Articles [262 Associated PubMed Articles listed on BioPortfolio]

A highly proliferative group IIC intron from Geobacillus stearothermophilus reveals new features of group II intron mobility and splicing.

The thermostable Geobacillus stearothermophilus GsI-IIC intron is among the few bacterial group II introns found to proliferate to high copy number in its host genome. Here, we developed a bacterial g...

Intronic antisense Alu elements have a negative splicing effect on the inclusion of adjacent downstream exons.

Alu elements occupy 10% of the human genome. However, although they contribute to genomic and transcriptomic diversity, their function is still not fully understood. We hypothesized that intronic Alu ...

Structural accommodations accompanying splicing of a group II intron RNP.

Group II introns, the putative progenitors of spliceosomal introns and retrotransposons, are ribozymes that are capable of self-splicing and DNA invasion. In the cell, group II introns form ribonucleo...

Genome-wide identification, phylogenetic classification, and exon-intron structure characterisation of the tubulin and actin genes in flax (Linum usitatissimum).

Flax (Linum usitatissimum L.) is a valuable food and fiber crop cultivated for its quality fiber and seed oil. α-, β-, γ-tubulins and actins are the main structural proteins of the cytoskeleton. α...

Sequence and Haplotypes Variation of the Ovine Uncoupling Protein-1 Gene (UCP1) and Their Association with Growth and Carcass Traits in New Zealand Romney Lambs.

Uncoupling protein-1 gene () plays an important role in the regulation of thermogenesis, energy expenditure, and protection against oxidative stress. In this study, six separateregions: region-1 and r...

Clinical Trials [119 Associated Clinical Trials listed on BioPortfolio]

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002)

This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron and INTRON® A and the pop...

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to pl...

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well ...

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and PEG-Intron (Peginterferon alpha-2b) in patients with advance...

Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498)(COMPLETED)

This is an open label, randomized, comparative, multi-center study. Subjects will be screened within 2 weeks prior to study entry to establish eligibility. Subjects who meet all the sele...

Companies [8 Associated Companies listed on BioPortfolio]

Exon-Intron, Inc.

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of ...

INTRON BIO TECHNOLOGY

NIL

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Prosensa

Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression in ...

More Information about "Exon-Intron, Inc." on BioPortfolio

We have published hundreds of Exon-Intron, Inc. news stories on BioPortfolio along with dozens of Exon-Intron, Inc. Clinical Trials and PubMed Articles about Exon-Intron, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Exon-Intron, Inc. Companies in our database. You can also find out about relevant Exon-Intron, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record